Tumours derived from all three cell lines without chronic IFNγ pre-treatment demonstrated delayed growth in response to α-PD-1 therapy for at least one-week post-treatment before mice eventually succumbed to progressive tumour growth, with tumours derived from YUMM2.1 responding best, followed by CT26 and then MC38 (Fig. 1E–G). This evidence concerns the gene PDCD1 and neoplasm.